Positive results were seen across multiple signs and symptoms of dry eye disease (DED) in a phase 2 study of Palatin Technologies’ MCR pan-agonist, PL9643, in adults with mild, moderate, or severe DED. Continued development of PL9643 as a novel therapy for DED is supported by a planned phase 3 trial comparing PL9643 to vehicle in more than 300 patients with moderate to severe DED.

The Melanocortin Pathway: A New Target For Ocular Disease Therapy

2021-October

Therapeutically targeting the melanocortin pathway represents a novel approach to the treatment of ocular diseases. Synthetic MCr receptor agonists show promise in the treatment of uveitis and retinopathy in preclinical animal models and PL9643 has demonstrated efficacy in treating signs and symptoms of dry eye disease in humans.